

Die „Renaissance“ der Polymyxine

Ingo Stock, Bonn

Literatur

- Ainsworth GC, Brown AM, Brownlee G. "Aerosporin". An antibiotic produced by *Bacillus aerosporus* Greer. *Nature* 1947;160:263.
- Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, et al. Colistin-resistant isolates of *Klebsiella pneumoniae* emerging in intensive care unit patients: first report of a multicolonal cluster. *J Antimicrob Chemother* 2007;59:786–90.
- Bassetti M, Repetto E, Righi E, Boni S, et al. Colistin and rifampicin in the treatment of multidrug-resistant *Acinetobacter baumannii* infections. *J Antimicrob Chemother* 2008;61:417–20.
- Bedford Laboratories. Polymyxin B for injection. Bedford Laboratories, Bedford, OH, USA, 2009.
- Benedict RG, Langlykke AF. Antibiotic activity of *Bacillus polymyxa*. *J Bacteriol* 1947;54:24–5.
- Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2006;50:1953–8.
- Berlana D, Llop JM, Fort E, Badia MB, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. *Am J Health Syst Pharm* 2005;62:39–47.
- Bilavsky E, Schwaber MJ, Carmeli Y. How to stem the tide of carbapenemase-producing Enterobacteriaceae: proactive versus reactive strategies. *Curr Opin Infect Dis* 2010;23:327–31.
- Bratu S, Mooty M, Nichani S, Landman D, et al. Emergence of KPC-possessing *Klebsiella pneumoniae* in Brooklyn, New York: epidemiology and recommendations for detection. *Antimicrob Agents Chemother* 2005;49:3018–20.
- Bratu S, Tolaney P, Karumudi U, Quale J, et al. Carbapenemase-producing *Klebsiella pneumoniae* in Brooklyn, N.Y.: molecular epidemiology and in vitro activity of polymyxin B and other agents. *J Antimicrob Chemother* 2005;56:128–32.
- Brodsky IE, Ernst RK, Miller SI, Falkow S. Mig-14 is a *Salmonella* gene that plays a role in bacterial resistance to antimicrobial peptides. *J Bacteriol* 2002;184:3203–13.
- Brown DA, Tsang JC. Chemical and electrophoretic changes induced by polymyxin B on outer membrane components from *Serratia marcescens*. *J Antibiot (Tokyo)* 1978;31:603–9.
- Burntack MN, Woods DE. Isolation of polymyxin B-susceptible mutants of *Burkholderia pseudomallei* and molecular characterization of genetic loci involved in polymyxin B resistance. *Antimicrob Agents Chemother* 1999;43:2648–56.
- Campos MA, Vargas MA, Regueiro V, Llopart CM, et al. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. *Infect Immun* 2004;72:7107–14.
- Conway SP, Pond MN, Watson A, Etherington C, et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. *Thorax* 1997;52:987–93.
- Cox AD, Wilkinson SG. Ionizing groups in lipopolysaccharides of *Pseudomonas cepacia* in relation to antibiotic resistance. *Mol Microbiol* 1991;5:641–6.
- David MD, Gill MJ. Potential for underdosing and emergence of resistance in *Acinetobacter baumannii* during treatment with colistin. *J Antimicrob Chemother* 2008;61:962–4.
- Evans ME, Feola DJ, Rapp RP. Polymyxin B sulphate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. *Ann Pharmacother* 1999;33:960–7.
- Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. *J Hosp Infect* 2009;73:345–54.
- Falagas ME, Kasiakou SF. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. *Crit Care* 2006;10:R27.
- Falagas ME, Rafailidis PI. Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives. *Expert Opin Investig Drugs* 2008;17:973–81.
- Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. *Int J Antimicrob Agents* 2010;35:194–9.
- Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant gram-negative bacterial infections. *Clin Microbiol Infect* 2006;12:1227–30.
- Falagas ME, Rizos M, Bliziotis IA, Rellos K, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. *BMC Infect Dis* 2005;5:1–8.
- Fekety FR Jr, Norman PS, Cluff LE. The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. *Ann Intern Med* 1962;57:214–29.
- Forest Laboratories, UK Limited. Colomycin injection. Forest Laboratories, Bexley, Kent, Großbritannien, 2002.
- Furtado GH, d'Azevedo PA, Santos AF, Gales AC, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 2007;30:315–9.
- Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). *Clin Microbiol Infect* 2006;12:315–21.
- Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. *J Clin Microbiol* 2001;39:183–90.
- Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, et al. Treatment of multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. *Clin Infect Dis* 2003;36:1111–8.
- Groisman EA, Kayser J, Soncini FC. Regulation of polymyxin resistance and adaptation to low-Mg²⁺ environments. *J Bacteriol* 1997;179:7040–5.
- Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant *Pseudomonas aeruginosa* with aerosolized colistin. *Am J Respir Crit Care Med* 2000;162:328–30.
- Hancock REW. Peptide antibiotics. *Lancet* 1997;349:418–22.
- Hase S, Rietchel ET. The chemical structure of the lipid A component of lipopolysaccharides from *Chromobacterium violaceum* NCTC 9694. *Eur J Biochem* 1977;75:23–34.
- Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in *Acinetobacter* and its association with previous colistin therapy. *Antimicrob Agents Chemother* 2008;52:351–2.
- Helander IM, Yato Y, Kilpelainen I, Kostianen R, et al. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive *Klebsiella pneumoniae* 03. *Eur J Biochem* 1996;237:272–8.
- Hermesen ED, Sullivan CJ, Rotschafer JC. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. *Infect Dis Clin North Am* 2003;17:545–62.
- Rodriguez CH, Bombicino K, Granados G, Nastro M, et al. Selection of colistin-resistant *Acinetobacter baumannii* isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. *Diagn Microbiol Infect Dis* 2009;65:188–91.
- Hirsch EB, Tam VH. Detection and treatment options for *Klebsiella pneumoniae* carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. *J Antimicrob Chemother* 2010;65:1119–25.
- Horianopoulou M, Lambropoulos S, Papafragas E, Falagas ME. Effect of aerosolized colistin on multidrug-resistant *Pseudomonas aeruginosa* in bronchial secretions of patients without cystic fibrosis. *J Chemother* 2005;17:536–8.
- Huang J, Tang YQ, Sun JY. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant gram-negative bacterial infections. *Scand J Infect Dis* 2010;42:260–5.
- Jensen T, Pedersen SS, Garne S, Heilmann C, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic *Pseudomonas aeruginosa* lung infection. *J Antimicrob Chemother* 1987;19:831–8.

Dr. rer. nat. Ingo Stock, Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie, Pharmazeutische Mikrobiologie, Universität Bonn, Meckenheimer Allee 168, 53115 Bonn, E-Mail: Ingo_Stock@web.de

43. Kallel H, Bahloul M, Hergafi L, Akrouf M, et al. Colistin as salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. *Int J Antimicrob Agents* 2006;28:366–9.
44. Ko KS, Suh JY, Kwon KT, Jung S-I, et al. High rates of resistance to colistin and polymyxin B in subgroups of *Acinetobacter baumannii* isolates from Korea. *J Antimicrob Chemother* 2007;60:1163–7.
45. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, et al. Adverse effects of sodium colistinmethate. Manifestations and specific reaction rates during 317 courses of therapy. *Ann Intern Med* 1970;72:857–68.
46. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, et al. Hospital outbreak caused by *Klebsiella pneumoniae* producing KPC-2 beta-lactamase resistant to colistin. *J Hosp Infect* 2010;76:70–3.
47. Koyama Y, Kurosawa A, Tsuchiya A, Takakuta K. A new antibiotic “colistin” produced by spore-forming *Solirubra* bacteria. *J Antibiot* 1950;3:457–8.
48. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA, et al. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2007. Online unter http://www.p-e-g.org/ag_resistenz/main.htm (letzter Zugriff am 01.02.2011).
49. Kwa ALH, Loh C, Low JGH, Kurup A, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *Clin Infect Dis* 2005;41:754–7.
50. Landman D, Bratu S, Alam M, Quale J. Citywide emergence of *Pseudomonas aeruginosa* strains with reduced susceptibility to polymyxin B. *J Antimicrob Chemother* 2005;55:954–7.
51. Landman D, Bratu S, Kochar S, Panwar M, et al. Evolution of antimicrobial resistance among *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Klebsiella pneumoniae* in Brooklyn, N.Y. *J Antimicrob Chemother* 2007;60:78–82.
52. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. *Clin Microbiol Rev* 2008;21:449–65.
53. Levin AS, Barone AA, Penco J, Santos MV, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Clin Infect Dis* 1999;28:1008–11.
54. Lewis LA, Choudhury B, Balthazar JT, Martin LE, et al. Phosphoethanolamine substitution of lipid A and resistance of *Neisseria gonorrhoeae* to cationic antimicrobial peptides and complement-mediated killing by normal human serum. *Infect Immun* 2009;77:1112–20.
55. Li J, Nation RL, Milne RW, Turnidge JD, et al. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. *Int J Antimicrob Agents* 2005;25:11–25.
56. Li J, Nation RL, Turnidge JD, Milner RW, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. *Lancet Infect Dis* 2006;6:589–601.
57. Li J, Rayner CR, Nation RL, Owen RJ, et al. Heteroresistance to colistin in multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2006;50:2946–50.
58. Linden PK, Kusne S, Coley K, Fontes P, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant *Pseudomonas aeruginosa*. *Clin Infect Dis* 2003;37:e154–60.
59. Manchanda V, Sanchaita S, Singh NP. Multidrug resistant *Acinetobacter*. *J Glob Infect Dis* 2010;2:291–304.
60. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. *Crit Care* 2003;7:R78–83.
61. Mathur J, Waldor MK. The *Vibrio cholerae* ToxR-regulated porin *OmpU* confers resistance to antimicrobial peptides. *Infect Immun* 2004;72:3577–83.
62. Michalopoulos AS, Kasiakou SK, Mastora Z, Rellos K, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. *Crit Care* 2005;9:R53–9.
63. Miyajima Y, Hiramatsu K, Mizukami E, Morinaga R, et al. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 2008;32:437–40.
64. Moffatt JH, Harper M, Harrison P, Hale JDF, et al. Colistin resistance in *Acinetobacter baumannii* is mediated by complete loss of lipopolysaccharide production. *Antimicrob Agents Chemother* 2010;54:4971–7.
65. Monarch Pharmaceuticals, Inc. Coly-mycin parenteral. Monarch Pharmaceuticals, Bristol, TN, USA, 2002.
66. Montero M, Horcajada JP, Sorlí L, Alvarez-Lerma F, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant *Pseudomonas aeruginosa* infections. *Infection* 2009;37:461–5.
67. Moskowitz SM, Ernst RK, Miller SI. *PmrAB*, a two-component regulatory system of *Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. *J Bacteriol* 2004;186:575–9.
68. Motaouakkil S, Charra B, Hachimi A, Nejmi H, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant *Acinetobacter baumannii*. *J Infect* 2006;53:274–8.
69. Nicas TI, Hancock REW. Alteration of susceptibility to EDTA, polymyxin B and gentamicin in *Pseudomonas aeruginosa* by divalent cation regulation of outer membrane protein H1. *J Gen Microbiol* 1983;129:509–17.
70. Nordmann P, Cuzon G, Naas T. The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *Lancet Infect Dis* 2009;9:228–36.
71. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. *Antimicrob Agents Chemother* 2003;47:2659–62.
72. Park YK, Jung S-I, Park K-H, Cheong HS, et al. Independent emergence of colistin-resistant *Acinetobacter* spp. isolates from Korea. *Diagn Microbiol Infect Dis* 2009;64:43–51.
73. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev* 2008;21:538–82.
74. Petrosillo N, Chinello P, Proietti MF, Cecchini L, et al. Combined colistin and rifampicin therapy for carbapenem-resistant *Acinetobacter baumannii* infections: clinical outcome and adverse events. *Clin Microbiol Infect* 2005;11:682–4.
75. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. *Clin Microbiol Infect* 2008;14:816–27.
76. Pintado V, San Miguel LG, Grill F, Mejia B, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. *J Infect* 2008;56:185–90.
77. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: an emerging public-health concern. *Lancet Infect Dis* 2008;8:159–66.
78. Reina R, Estenssoro E, Saenz G, Canales HC, et al. Safety and efficacy of colistin in *Acinetobacter* and *Pseudomonas* infections: a prospective cohort study. *Intensive Care Med* 2005;31:1058–65.
79. Reis AO, Luz DA, Tognum MC, Sader HS, et al. Polymyxin-resistant *Acinetobacter* spp. isolates: what is next? *Emerg Infect Dis* 2003;9:1025–7.
80. Rios FG, Luna CM, Maskin B, Valiente AS, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. *Eur Respir J* 2007;30:307–13.
81. Sabuda DM, Laupland K, Pitout J, Dalton B, et al. Utilization of colistin for treatment of multidrug-resistant *Pseudomonas aeruginosa*. *Can J Infect Dis Med Microbiol* 2008;19:413–8.
82. Sidorczyk Z, Zahringer U, Rietschel ET. Chemical structure of the lipid A component of the lipopolysaccharide from a *Proteus mirabilis* re-mutant. *Eur J Microbiol* 1983;137:15–22.
83. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. *J Antimicrob Chemother* 2004;54:566–9.
84. Spinosa MR, Progida C, Talà A, Cogli L, et al. The *Neisseria meningitidis* capsule is important for intracellular survival in human cells. *Infect Immun* 2007;75:3594–603.
85. Srinivasan A, Patel JB. *Klebsiella pneumoniae* carbapenemase-producing organisms: an ounce of prevention really is worth a pound of cure. *Infect Control Hosp Epidemiol* 2008;29:1107–9.
86. Stanly PG, Shepherd RG, White HJ. Polymyxin: a new chemotherapeutic agent. *Johns Hopk Hosp Bull* 1947;81:43–54.
87. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. *Annu Rev Biochem* 1977;46:723–63.
88. Suh J-Y, Son JS, Chung DR, Peck KR, et al. Nonclonal emergence of colistin-resistant *Klebsiella pneumoniae* isolates from blood samples in South Korea. *Antimicrob Agents Chemother* 2010;54:560–2.
89. Suzuki T, Hayashi K, Fujikawa K, Tsukamoto K. The chemical structure of polymyxin E: the identities of polymyxin E1 with colistin A and polymyxin E2 with colistin B. *J Biochem (Tokyo)* 1965;57:226–7.
90. Tallgren LG, Liewendahl K, Kuhlbaeck B. The therapeutic success and nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal function. *Acta Med Scand* 1965;177:717–28.
91. Tam VH, Chang K-T, Abdelraouf K, Brioso CG, et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2010;54:1160–4.
92. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant *Acinetobacter baumannii* and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. *Antimicrob Agents Chemother* 2007;51:3413–5.
93. Tascini C, Gemignani G, Palumbo F, Leonildi A, et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant *Pseudomonas aeruginosa* diabetic foot infections with or without osteomyelitis. *J Chemother* 2006;18:648–51.

94. Tóth A, Damjanova I, Puskás E, Jánvári L, et al. Emergence of a colistin-resistant KPC-2-producing *Klebsiella pneumoniae* ST258 clone in Hungary. *Eur J Clin Microbiol Infect Dis* 2010;29:765–9.
95. Tran AX, Whittimore JD, Wyrick PB, McGrath SC, et al. The Lipid A 1-phosphatase of *Helicobacter pylori* is required for resistance to the antimicrobial peptide polymyxin. *J Bacteriol* 2006;188:4531–41.
96. Walkty A, DeCorby M, Nichol K, Karlowsky JA, et al. In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007–2008. *Antimicrob Agents Chemother* 2009;53:4924–6.
97. Winfield MD, Groisman EA. Phenotypic differences between *Salmonella* and *Escherichia coli* resulting from the disparate regulation of homologous genes. *Proc Natl Acad Sci USA* 2004;101:17162–7.
98. Winfield MD, Latifi T, Groisman EA. Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in *Yersinia pestis*. *J Biol Chem* 2005;280:14765–72.
99. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. *J Antimicrob Chemother* 2007;60:1206–15.